Prexige Still Postponed: Novartis To Resubmit COX-2 Inhibitor In U.S. In 2007
Executive Summary
Novartis plans to resubmit Prexige (lumiracoxib) in the U.S. in the first half of 2007; approval of the oral COX-2 inhibitor in the European Union and Canada for treatment of osteoarthritis symptoms was announced Nov. 7
You may also be interested in...
Novartis Is Confident In Prexige’s Prospects Despite Arcoxia AC Debacle
Novartis is confident its COX-2 inhibitor Prexige does not raise the same safety concerns cited by an FDA advisory committee in recommending against approval of Merck's COX-2 agent Arcoxia
Novartis Is Confident In Prexige’s Prospects Despite Arcoxia AC Debacle
Novartis is confident its COX-2 inhibitor Prexige does not raise the same safety concerns cited by an FDA advisory committee in recommending against approval of Merck's COX-2 agent Arcoxia
Novartis Adds Reps In Face Of Big Pharma Cuts, Citing Pipeline, Portfolio
Novartis' decision to expand its sales force by 1,000 reps in the U.S. - in the face of cuts by many of its competitors - reflects the growth potential of the firm's product portfolio and the strength of its pipeline, Pharmaceuticals CEO Thomas Ebeling said